2 completed, 1 recruiting, 1 unknown. 2 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Recruiting 1 |
| Phase 3 | 2 | Completed 1, Unknown 1 |
| Phase 1 | 1 | Completed 1 |
Follow EBI-005: new trials by email Literature Review of EBI-005 trials Research Report on EBI-005
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS) isunakinra - Colorectal Cancer Metastatic | Phase 2 | Recruiting | Buzzard Pharmaceuticals | 20 | 2025-01-30 | 2026-10-23 |
| Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors Isunakinra, PD-(L)1 Inhibitor - Solid Tumor, Adult | Phase 1 / Phase 2 | Completed | Buzzard Pharmaceuticals | 15 | 2020-09-01 | 2024-08-06 |
| A Multi-Center Environmental Study for the Treatment of Moderate to Severe Ocular Allergic Conjunctivitis EBI-005, Placebo Comparator - Allergic Conjunctivitis (AC) | Phase 3 | Completed | Eleven Biotherapeutics | 250 | 2015-07-01 | 2016-02-11 |
| Study of EBI-005 in Dry Eye Disease (DED) EBI-005, Placebo - Dry Eye | Phase 3 | Unknown | Eleven Biotherapeutics | 188 | 2015-04-01 | 2015-06-04 |
Colorectal Neoplasms (1) · Conjunctivitis, Allergic (1) · Disease (1) · Dry Eye Syndromes (1) · Neoplasm Metastasis (1)
Buzzard Pharmaceuticals (2) · Eleven Biotherapeutics (2)
United States (4)